Recently, Guardant Health, Inc. announced exciting updates for 2021 which is bringing the company closer to its vision of transforming cancer care across the continuum. This includes the introduction of Guardant Reveal, the first blood-only liquid biopsy for residual disease and recurrence monitoring for early-stage colorectal cancer (CRC), expanded clinical utility of Guardant360 for advanced cancer patients, and the LUNAR-2 ECLIPSE trial for early-stage CRC screening which is expected to finish enrollment this year. Click on the following link to see the complete presentation from the J.P. Morgan 39th Annual Healthcare Conference: https://lnkd.in/gTa2Q6z
Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at email@example.com or contact us on WhatsApp: +65 8940 0360.
Guardant360®. Test. Take Action.